Protective effect of arachidonic acid and linoleic acid on 1-methyl-4-phenylpyridinium-induced toxicity in PC12 cells by Kim Tang
Tang Lipids in Health and Disease 2014, 13:197
http://www.lipidworld.com/content/13/1/197RESEARCH Open AccessProtective effect of arachidonic acid and linoleic
acid on 1-methyl-4-phenylpyridinium-induced
toxicity in PC12 cells
Kim San TangAbstract
Background: Parkinson’s disease is a neurodegenerative disorder that is being characterized by the progressive loss
of dopaminergic neurons of the nigrostriatal pathway in the brain. The protective effect of omega-6 fatty acids is
unclear. There are lots of contradictions in the literature with regard to the cytoprotective role of arachidonic acid.
To date, there is no solid evidence that shows the protective role of omega-6 fatty acids in Parkinson’s disease. In
the current study, the potential of two omega-6 fatty acids (i.e. arachidonic acid and linoleic acid) in alleviating
1-methyl-4-phenylpyridinium (MPP+)-induced cytotoxicity in PC12 cells was examined.
Methods: Cultured PC12 cells were either treated with MPP+ alone or co-treated with one of the omega-6 fatty
acids for 1 day. Cell viability was then assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay.
Results: Cells treated with 500 μM MPP+ for a day reduced cell viability to ~70% as compared to control group.
Linoleic acid (50 and 100 μM) significantly reduced MPP+-induced cell death back to ~85-90% of the control value.
The protective effect could be mimicked by arachidonic acid, but not by ciglitazone.
Conclusions: Both linoleic acid and arachidonic acid are able to inhibit MPP+-induced toxicity in PC12 cells. The
protection is not mediated via peroxisome proliferator-activated receptor gamma (PPAR-γ). Overall, the results suggest
the potential role of omega-6 fatty acids in the treatment of Parkinson’s disease.
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Parkinson’s disease is a neurodegenerative disease that
affects 1-2% of people above 65 years of age. In popula-
tion over 85 years old, the prevalence of the disease in-
creases to 3-5% [1]. The disease is being characterized
by the progressive loss of dopaminergic neurons in the
midbrain's substantial nigra [2]. The clinical motor
symptoms that are associated with Parkinson’s disease
are bradykinesia, involuntary tremor, postural instabil-
ity, muscle weakness and rigidity [3].
PC12, a cell line derived from a pheochromocytoma
of the rat adrenal medulla, is used widely as a model
for catecholaminergic transmission. These cells are
popular because they are able to synthesize and releaseCorrespondence: tang.kim.san@monash.edu
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unless otherwise stated.catecholamines in a similar manner as dopaminergic
neurons and adrenal medullary chromaffin cells [4].
Unlike chromaffin cells, PC12 cells only synthesize very
small amount of adrenaline [5-7]. PC12 cells treated
with 1-methyl-4-phenylpyridinium (MPP+), a neurotoxin
that causes parkinsonism, were extensively used as a
model of Parkinson’s disease in vitro [8-10]. MPP+ has
been shown to induce apoptosis, dissipation of mitochon-
drial membrane permeability, and elevation of intracellu-
lar reactive oxygen species level in PC12 cells [11].
Omega-6 fatty acids are polyunsaturated fatty acids
[12]. These fatty acids play a crucial role in growth de-
velopment and brain function. There are several types of
omega-6 fatty acids, and the key ones are linoleic acid
and arachidonic acid. Linoleic acid can be obtained from
diet, such as vegetable oil [13]. Linoleic acid cannot be
synthesized by the body, and thus it is necessary toan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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linoleic acid is classified as one of the essential fatty
acids. On the other hand, arachidonic acid is not consid-
ered as one of the essential fatty acids since the body
can synthesize arachidonic acid from linoleic acid [15].
Meat, fish, and egg are the main dietary source of ara-
chidonic acid [13,16,17].
To date, there is no direct evidence that shows the pro-
tective role of omega-6 fatty acids in in vitro Parkinson’s
model. This is the first study to examine the protective
role of linoleic acid and arachidonic acid and their poten-
tial interaction in a Parkinson’s disease model simulated
by exposing PC12 cells to MPP+ neurotoxin.
Methods
Materials
PC12 cells were purchased from the American Type
Culture Collection (ATCC, CRL-1721.1). Dulbecco's
Modified Eagle Medium (DMEM), horse serum and fetal
bovine serum were Gibco products of Life Technologies
(Grand Island, NY, USA). Arachidonic acid, linoleic
acid, methylthiazolyldiphenyl-tetrazolium bromide (MTT),
ciglitazone and bisphenol A diglycidyl ether (BADGE)
were obtained from Sigma-Aldrich (Malaysia). 96-well
culture plates were purchased from Corning (Lowell,
MA, USA).
Cell culture
PC12 cells were grown in DMEM medium, containing
4.5 g/L glucose, supplemented with 10% horse serum
and 5% fetal bovine serum. The cells were maintained at
37°C in an environment consisting of 95% air and 5%
carbon dioxide. The medium was changed every other
day. For the experiments, the cells were seeded at a
density of 5 × 104 cells per well in 96-well culture plates
for an overnight before subjected to experimental
treatment.
Induction of cell death
Twenty-four hours after plating, MPP+ was used to in-
duce death in PC12 cells. To examine the effect of
omega-6 fatty acids, cultures were exposed to linoleic
acid or arachidonic acid alone or with MPP+ for 1 day.
These fatty acids were initially diluted in DMSO to a
stock concentration of 200 mM and stored in −20°C be-
fore use.
Cell viability assay
The protective effect of compounds on cell viability
was assessed by using MTT conversion assay. The cells
were incubated with MTT solution (final concentration,
0.5 mg/ml) in the dark for 4 h at 37°C. The dark-blue
formazan crystals formed in intact cells were solubi-
lized with isopropanol solution acidified with 0.1 NHCl. The optical density of each well was measured
with a microplate reader at the test wavelength of
570 nm. Optical density is directly proportional to the
number of living cells in culture. The data obtained
were then expressed as percentage of viable cells rela-
tive to the untreated control group value.
Statistical analysis
Each treatment was performed in duplicate or triplicate
and each experiment was repeated at least three times.
Statistical differences between experimental groups were
determined by performing one-way analysis of variance
(ANOVA) and the Newman-Keuls multiple comparison
test. A level of P < 0.05 was considered statistically
significant.
Results
In this study, MPP+ was employed as a tool to study the
cell death. This compound causes loss of dopaminergic
marker in the nigrostriatal neurons and a significant
drop of dopamine level in the striatum of primates.
Thus, MPP+-induce neuronal cell death is one of the
common experimental models that is widely used to
study the pathogenesis of Parkinson’s disease [8-10].
MPP+ is able to induce many pathological changes asso-
ciated with cellular dysfunction such as neuronal cyto-
skeletal lesions, apoptosis, increases in mitochondrial
permeability and intracellular calcium level. Treatment
with MPP+ (500 μM) alone for 1 day yielded significant
cell death to ~70% of control value (Figure 1).
Here, the potential protective role of two omega-6
fatty acids, namely arachidonic acid and linoleic acid
was explored. PC12 cells were treated with MPP+ in the
presence or absence of linoleic acid or arachidonic acid.
As measured by MTT assay, MPP+-induced toxicity
was attenuated in a dose-dependent manner when cul-
tures were exposed to linoleic acid (1–100 μM) for
1 day (Figure 1). A significant amount of protection
was observed in PC12 cells treated with linoleic acid
(50–100 μM) when compared to MPP+-treated group
(Figure 1). The cell viability was significantly increased
to 85% and 90% of control value when treated with 50 μM
and 100 μM of linoleic acid, respectively (Figure 1). Treat-
ment with linoleic acid alone had no prominent effect on
cell viability (Figure 2).
The cell survival was enhanced when treated with ara-
chidonic acid alone (Figure 3). Interestingly, a severe
toxic effect was seen when the PC12 cells were treated
with a high dose of arachidonic acid (Figure 3). The ma-
jority of PC12 cells were dead when treated with
100 μM of arachidonic acid. Despite of the high dose,
treatment with arachidonic acid (25–50 μM) completely
reverted MPP+-induced cell death back to or above
the untreated control value (Figure 4). The protection is
Figure 1 Linoleic acid inhibits MPP+-induced cell death. Cultured PC12 cells were subjected to 500 μM MPP+ in the absence or presence of
different concentrations of linoleic acid (LA) (1–100 μM) for 24 h at 37°C. Number of viable cells was determined by MTT assay. The control was
set to 100% survival. Data are means ± SEM (n = 3). Data were analyzed using one-way ANOVA and Neuman-Keuls’ test. Means with superscripts a
and b are significantly different at P < 0.05 comparing control and 500 μM MPP+ only-treated groups, respectively.
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activated receptor gamma (PPAR-γ) since the effect
could not be mimicked by agonist ciglitazone (1 μM)
(Figure 5). Furthermore, the cell viability upon MPP+-
treatment is slightly higher, although statistically insig-
nificant, in the presence of a PPAR-γ antagonist,Figure 2 The effect of linoleic acid on PC12 cells. PC12 cells in culture
for 24 h at 37°C. Number of viable cells was determined by MTT assay. The
(n = 3). Data were analyzed using one-way ANOVA and Neuman-Keuls’ test
compared to the control.BADGE (10 μM). Although both arachidonic acid and
linoleic acid show significant protection at 10 μM and
50 μM concentrations, respectively, simultaneous treat-
ment of both fatty acids did not produce any add-
itional protective effect against MPP+-induced cell
death (Figure 6).were exposed to increasing doses of linoleic acid (LA) from 1–100 μM
control was set to 100% survival. Data are expressed as means ± SEM
. None of the data from treated-groups are statistically different when
Figure 3 The effect of arachidonic acid on PC12 cells. Cultured PC12 cells were subjected to various concentrations arachidonic acid (AA)
(1–100 μM) for 24 h at 37°C. Number of viable cells was determined by MTT assay. The control was set to 100% survival. Data shown are means ± SEM
(n = 3). Data were analyzed using one-way ANOVA and Neuman-Keuls’ test. Means with superscript a are significantly different at P < 0.05 comparing
control.
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In the current work, MPP+-induced PC12 cell death was
attenuated by two omega-6 fatty acids, namely linoleic
acid and arachidonic acid. The latter is a type of polyun-
saturated fatty acids, which is found mainly in brainFigure 4 Arachidonic acid attenuates MPP+-induced cell death. PC12 c
acid (AA) (1–50 μM) for 24 h at 37°C. Number of viable cells was determined
means ± SEM (n = 3). Data were analyzed using one-way ANOVA and Neuma
P < 0.05 comparing control and 500 μM MPP+ only-treated groups, respectivetissues. It has many physiological roles, for example,
blood clotting, brain development and can act as a sig-
naling molecule in the brain [18-20]. The role of arachi-
donic acid on cytoprotection is rather controversial from
the literature. The enzymatic oxidation of arachidonicells were exposed to 500 μM MPP+ in the different doses of arachidonic
by MTT assay. The control was set to 100% survival. Data are expressed as
n-Keuls’ test. Means with superscripts a and b are significantly different at
ly.
Figure 5 Ciglitazone does not attenuate MPP+-induced cell death. PC12 cells were treated with 500 μM MPP+, 1 μM ciglitazone, 10 μM
BADGE, or combinations of these compounds for 24 h at 37°C. Number of viable cells was determined by MTT assay. The control was set to
100% survival. Data are means ± SEM (n = 3). Data were analyzed using one-way ANOVA and Neuman-Keuls’ test. Means with superscripts a and b
are significantly different at P < 0.05 comparing control and 500 μM MPP+ only-treated groups, respectively.
Figure 6 Simultaneous treatment with arachidonic acid and linoleic acid. PC12 cells were exposed to 500 μM MPP+ in the absence or
presence of 10 μM arachidonic acid (AA), 50 μM linoleic acid (LA) or combination of both, for 24 h at 37°C. Number of viable cells was determined by
MTT assay. The control was set to 100% survival. Data are means ± SEM (n = 3). Data were analyzed using one-way ANOVA and Neuman-Keuls’ test.
Means with superscripts a and b are significantly different at P < 0.05 comparing control and 500 μM MPP+ only-treated groups, respectively.
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as prostacyclins, thromboxane A2 and leukotrienes [21].
Arachidonic acid has been shown to cause apoptosis and
cell death in many different cell types [22-25]. Many
studies reported that arachidonic acid is cytotoxic even
at concentartions of 50–100 μM in most cell lines [26].
Concentrations of arachidonic acid above 100 μM are
able to induce necrosis in a variety of cells. Moreover,
intravenous injection of high dose of arachidonic acid
has been shown to cause sudden death in rabbit [27].
However, it is uncertain if arachidonic acid has any dir-
ect effect on cell viability on in vivo study. In this study,
high dose of arachidonic acid (100 μM) has been shown
to cause severe toxicity to cultured PC12 cells (Figure 3).
Despite this, concentrations of arachidonic acid up to
50 μM are protective against MPP+ insult in these cells
(Figure 4). In addition, treatment with arachidonic acid
alone improves the percentage of viable PC12 cells
above the control value. The results of this study are
consistent with several other reports demonstrating that
arachidonic acid is indeed protective. For example, ara-
chidonic acid can protect rat hippocampal slices against
oxidative stress induced by hydrogen peroxide and glu-
tamate [28]. Furthermore, arachidonic acid can also pro-
tect rat cardiac myocytes and gastric mucosa against
ischemic and ethanol insults, respectively [29,30].
Astrocytes are the major source of arachidonic acid in
the brain [31-33]. Astrocytes can synthesize and release
arachidonic acid. Astrocytes and neurons are located very
close to one another. Thus, astrocytes are able to supply
neurons with arachidonic acid. Astrocytes play significant
roles in maintaining neuronal function and survival in the
brain. The protective roles of astrocytes depend mainly on
the substances that they release into and take up from the
extracellular space, a microenvironment that is shared be-
tween astrocytes and neurons. In Parkinson’s disease, the
role of astrocytes might be impaired. For example, MPP+
has been demonstrated to induce toxicity in astrocyte cul-
ture. MPP+ causes failure of energy metabolism in astro-
cytes and therefore, impairs the glutamate uptake capacity
of these cells [34]. High level of extracellular glutamate
can cause excitotoxicity to the surrounding neurons
[35-37]. In addition to that, a lack of neuronal supply of
arachidonic acid could also be one of the factors that
causes neuronal death in Parkinson’s disease. Hence, fur-
ther studies could be carried out to elucidate the effect of
endogenous arachidonic acid by either using pre-
conditioned media or astrocyte co-cultures.
The critical micelle concentration (CMC) values re-
ported for arachidonic acid and linoleic acid are quite
similar (~10-60 μM) [26,38], hence concentrations above
this level could form micelles that reduce the effectiveness
of the compound when introduced into the medium. Des-
pite of the potential limitation, both arachidonic acid andlinoleic acid were found to be able to protect against
MPP+-induced cell death in a dose-dependent manner
(Figures 1 and 4). In addition, a significant amount of
protection started to be seen when the cells treated with
2.5 μM of arachidonic acid, a concentration below its
CMC value (Figure 4). Although some concentrations used
here were above the CMC, biophysical analyses of fatty
acids in water showed that micelles were rarely formed
below pH 9.0 [39]. In fact, the pH of culture medium used
in this study was maintained as close to the physiological
pH as possible using CO2. Furthermore, the bicarbonate
presents in the culture medium is a weak buffer and is able
to prevent drastic pH changes. Bicarbonate is not only a
non-toxic substance, but has nutritional value.
In addition to cytoprotection, arachidonic acid also ex-
hibits growth-promoting effects on PC12 cells. The op-
tical density obtained from MTT assay is directly
proportional to the cell viability provided that there is
no any other inference substance in this assay. Micelle
formation is likely to be increased when higher concen-
trations of fatty acids are used. Therefore, one may argue
that the formation of micelles may interfere with the op-
tical density measurement of MTT assay and thus pro-
duces a false dose-dependent increase in cell viability as
seen in arachidonic acid treatment (Figure 3). However,
this is unlikely to be the case because the trend was not
obvious when the cells were treated with increasing con-
centrations of linolenic acid, a compound with similar
CMC value as arachidonic acid (Figure 2).
It has also been reported that arachidonic acid concen-
tration in the cerebrospinal fluid is ~1 μM [40]. How-
ever, due to the close anatomical proximity between
neurons and astocytes, it is not surprising for the neu-
rons to be instantly exposed to high local concentration
of arachidonic acid physiologically beyond the level that
was measured from cerebrospinal fluid. Thus, the con-
centrations used in this study could be physiologically
relevant and it is not unrealistic to see such a protection
at these concentrations.
PPAR-γ is a nuclear receptor which acts as a transcrip-
tional regulator of multiple genes and subsequently pro-
moting cell differentiation, proliferation and survival in
many cell types. It has been reported that PPAR-γ is
present in PC12 cells [41,42]. Previous studies have
shown that arachidonic acid and its metabolites such as
prostaglandins can activate PPAR-γ [43]. The results
from this study show that ciglitazone, a PPAR-γ agonist,
could not protect the PC12 cells from MPP+-induced
death (Figure 5). Thus, the involvement of PPAR-γ sig-
nalling pathway in cytoprotection can be excluded from
this study.
Linoleic acid has been shown to be able to protect
necrotic and apoptotic cell death induced by palmitic
acid [44]. In this study, linoleic acid has also been shown
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Linoleic acid is the precursor for the synthesis of arachi-
donic acid [45]. Most mammals, including human are
able to convert linoleic acid to arachidonic acid [15].
The metabolic conversion occurs mainly in liver and
brain, and is mediated by delta-5 and delta-6 desaturase
[46]. In fact, these enzymes have been shown to be
present in various mammalian cells and tissues [47,48].
Interestingly, the metabolic conversion of linoleic acid to
arachidonic acid has also been demonstrated in many
cultured mammalian cells [49,50]. Nonetheless, the pos-
sibility that the protective effect of linoleic acid is
achieved via the in vitro metabolic conversion pathway
cannot be excluded. These two fatty acids are likely to
share and mediate the same downstream protective
mechanisms since no additional protection against MPP
+-induced cell death was seen when PC12 cells were
simultaneously treated with linoleic acid and arachidonic
acid (Figure 6).
Conclusions
In conclusion, both linoleic acid and arachidonic acid can
effectively protect PC12 cells against toxicity caused by
MPP+. However, further studies are required to elucidate
the protective pathway of these fatty acids. For instance,
the mechanisms that lead to cellular toxicity such as anti-
oxidant, anti-inflammatory and anti-apoptotic properties
shall be explored further. The findings from this study
suggest that omega-6 fatty acids could have a potential
therapeutic or preventive role in Parkinson’s disease.
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